CJC-1295 (No DAC)
Mod GRF 1-29
Short-acting GHRH analogue without DAC modification. Produces physiological GH pulses when administered proximate to natural GH release windows. Often combined with GHRP peptides for synergistic GH output.
Format
5mg / vial
Purity
>99.0%
Category
Performance
Storage
2–8 °C
Research Price
€69
5mg / vial
RESEARCH USE ONLY
This compound is sold exclusively for in-vitro laboratory research. It is not intended for human consumption, therapeutic use, or self-administration. You must be 18+ and a qualified researcher to purchase.
Complete Your Research with the Pen Kit
Precise, painless, repeatable. The clinical-grade injection pen with 32G ultra-fine needles, bacteriostatic water, and your choice of peptide — ready to use out of the box.
€189
View details →Research Protocol Bundles
GH Secretagogue Stack
CJC-1295 + Ipamorelin
The most widely studied growth-hormone peptide combination. CJC-1295 (no DAC) provides a clean GHRH pulse; Ipamorelin selectively stimulates GH release without cortisol or prolactin elevation.
Bundle total
€148
8% bundle saving
Documented Research Parameters
Research Dose
100 mcg
Frequency
1–2× daily (combine with GHRP for synergy)
Duration
8–16 weeks
Half-Life
~30 minutes
Route(s)
Subcutaneous
Solubility
Water
Reconstitution
2 ml bacteriostatic water per 5 mg vial
Key Research Findings
Mod GRF 1-29 — identical peptide to CJC-1295 without Drug Affinity Complex modification.
Short half-life (~30 min) preserves natural pulsatile GH secretion patterns in research models.
Administration 30–60 minutes before major GH release windows maximises pulse amplitude.
Combined with GHRP: GHRH and GHRP act synergistically on somatotrophs via distinct receptor types.
Administration Reference
Subcutaneous injection in the abdominal region. Typically administered 5–10 minutes before, or simultaneously with, a GHRP peptide. Pre-sleep and pre-exercise timing is explored in GH secretion research. Rotate injection sites across the abdomen.
Documented Combination Protocols
The gold-standard GH research stack — GHRH analogue + selective GHRP. Synergistic GH output with high receptor selectivity.
Classic GHRH+GHRP combination with pronounced appetite modulation for ghrelin biology research.
IMPORTANT RESEARCH DISCLAIMER
This compound is for in-vitro research and laboratory use only. It has not been evaluated or approved by any regulatory authority for human therapeutic use. It must not be used as a food, drug, or cosmetic. SYNTHEXA assumes no liability for misuse. Handle in accordance with Good Laboratory Practice.